Tick-borne encephalitis vaccine - Bavarian Nordic
Alternative Names: EncepurLatest Information Update: 22 Jun 2020
At a glance
- Originator Novartis
- Developer GlaxoSmithKline
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Encephalitis
Most Recent Events
- 18 Jun 2020 Bavarian Nordic and Valneva SE enters into an agreement for the marketing and distribution of tick-borne encephalitis in Germany, Switzerland, Canada and USA
- 31 Dec 2019 GlaxoSmithKline (GSK) completes divestiture of tick-borne encephalitis vaccine to
- 22 Oct 2019 Bavarian Nordic enters into a purchase agreement with GlaxoSmithKline (GSK), to purchase Tick-borne encephalitis vaccine (Encepur)